Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABERCROMBIE & FITCH CO /DE/
Report date June 15, 2017 · Filed June 16, 2017
Section 16 reporting ended · disclosed 2017-06-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security | Direct | 32,660 |
Reported balance
After 2017-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-15 · Exercise / conversion · Acquired 8,043 · Balance 32,660 F1: Each share of phantom stock represents a right to receive one share of Issuer's common stock. F2: The shares of phantom stock become payable in the form of Common Stock of the Issuer upon the reporting person's termination of service as a director. F3: Total includes accrued dividends. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-15 · Exercise / conversion · Disposed 8,043 · Balance 0 F4: This award converts to Common Stock of the Issuer on a 1-for-1 basis. F5: Vests the earlier of the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of phantom stock represents a right to receive one share of Issuer's common stock.
F2: The shares of phantom stock become payable in the form of Common Stock of the Issuer upon the reporting person's termination of service as a director.
F3: Total includes accrued dividends.
F4: This award converts to Common Stock of the Issuer on a 1-for-1 basis.
F5: Vests the earlier of the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders.
AVADEL PHARMACEUTICALS PLC
Report date May 09, 2019 · Filed May 10, 2019
Section 16 reporting ended · disclosed 2019-05-10. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2016 Filed Sep 6, 2016 17:27 UTC | AVADEL PHARMACEUTICALS PLC FLML · Entity 65991 | PurchaseADSs | 10,000 | $13.52 | $135,190.00 |
DisclosureSEC source: 0001144204-16-122915 · v448400_4.xml · nonDerivative · entry 1 STAPLETON CRAIG R · CIK 0001207106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 519,678 F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.35 to $13.75, inclusive. The reporting person undertakes to provide to Flamel Technologies S.A., any security holder of Flamel Technologies S.A., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2). Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 22:49 UTC | ABERCROMBIE & FITCH CO /DE/ ANF · Entity 3771 | PurchaseClass A Common Stock | 10,000 | $17.65 | $176,500.00 |
DisclosureSEC source: 0001225208-16-038875 · doc4.xml · nonDerivative · entry 1 STAPLETON CRAIG R · CIK 0001207106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,398 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.